Clinical Trial Search

Primary: Number of Participants With Hematology Abnormalities of Potential Clinical Importance (PCI) — 3; 0; 0; 0 Participants

Primary: Aphasia Testing as Evaluated by the Boston Naming Test (BNT) - Baseline — 33.43; 18.29; 28.57; 41.00 units on a scale

Primary: CL/F : Apparent Clearance — 0.0106 L/h

Primary: Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI) in the 6th Week of Treatment — 2.855; 2.317 Millilitre/ meter^2 (mL/m^2) — p=0.6331

Primary: Change From Baseline (7-days Post Discharge) to 90-days in the PROMIS-10 Global Quality of Life, Physical Health T-scores (Patient) — 0.293; 1.263; 3.663 change in…

Primary: Cumulative Narcotic Use — 27; 45 mg — p=0.006

Primary: Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A) — -0.37; -0.36; -0.07 g/minute — p=<0.0001

Primary: Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120 — 5.3; 327.9; 6.0; 1742.5 titer

Primary: Percentage of Participants With Composite of Venous Thrombotic Event (VTE) or Major Bleeding Event (MBE) According to International Society on Thrombosis and Haemostasis…

Primary: Change in Vascular Inflammation — -0.1015; 0.1442; -0.0151 TBR max — p=0.0012

Primary: Adherence Score — 0.57; 0.54; 0.59 score on a scale

Primary: Incidence of Severe Malaria Meeting Case Definition 1 — 0.001; 0.002; 0.002; 0.004 events per person-year — p=0.2235

Primary: Best-corrected Visual Acuity — 52.9 ETDRS letters

Primary: To Measure the Distribution of Nasal Sprays and Drops. — 18; 17; 16; 17 nasal cavities (right and left sides)

Primary: Technical Effectiveness as Assessed by Number of Sutures Required to Complete Closure at the Camera Port Site — 2; 1.84 number of sutures